Protagenic Therapeutics

Protagenic Therapeutics Interest Coverage

The Interest Coverage Ratio of Protagenic Therapeutics (PTIX) as of Nov 16, 2026 is -5.84. In the previous year, Interest Coverage Ratio was -59.88 — a change of -90.25% (higher).

Interest Coverage

-5.84

YoY

-90.25%

Last updated:

Interest Coverage Ratio of Protagenic Therapeutics is 2025 -5.84 . Interest Coverage Ratio of Protagenic Therapeutics was 2024 -59.88 . It decreases by -90.25% higher compared to the previous year.

The Protagenic Therapeutics Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
-23.65 USD
Jan 1, 2018
-11.57 USD
Jan 1, 2019
-6.95 USD
Jan 1, 2021
-10.35 USD
Jan 1, 2023
-9.56 USD
Jan 1, 2024
-59.88 USD
Jan 1, 2025
-5.84 USD
The Protagenic Therapeutics Interest Coverage history
YEARInterest CoverageYoY
-5.84-90.25%
-59.88+526.36%
-9.56-7.63%
-10.35+48.85%
-6.95-39.90%
-11.57-51.08%
-23.65—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Protagenic Therapeutics Stock analysis

What does Protagenic Therapeutics do? Protagenic Therapeutics, Inc. develops therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound PT00114 is a synthetic TCAP-1 peptide designed to dampen overactive stress responses. The company also has a portfolio of earlier stage neuropeptides targeting the TCAP pathway in preclinical evaluation. PT00114 has shown pre-clinical efficacy in animal models of depression, anxiety, substance abuse, addiction, and PTSD, including the Saleens test for opioid withdrawal. The company focuses on developing treatments for conditions where current therapies are limited or ineffective. Protagenic's products are developed for pharmaceutical companies and research institutions seeking novel treatments for neuropsychiatric disorders. The target segments include patients suffering from depression, anxiety, PTSD, and substance abuse disorders. The company's lead compound PT00114 and its neuropeptide portfolio are positioned as potential treatments for these conditions, with the aim of addressing unmet medical needs in mental health care. Protagenic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Protagenic Therapeutics stock

Interest Coverage Ratio of Protagenic Therapeutics is -5.84 in 2025.

Interest Coverage Ratio of Protagenic Therapeutics changed from -59.88 to -5.84, representing a -90.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Protagenic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Protagenic Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Protagenic Therapeutics

All Key Metrics — Protagenic Therapeutics